Targeting inflammation in the treatment of type 2 diabetes: time to start

Nat Rev Drug Discov. 2014 Jun;13(6):465-76. doi: 10.1038/nrd4275. Epub 2014 May 23.


The role of inflammation in the pathogenesis of type 2 diabetes and associated complications is now well established. Several conditions that are driven by inflammatory processes are also associated with diabetes, including rheumatoid arthritis, gout, psoriasis and Crohn's disease, and various anti-inflammatory drugs have been approved or are in late stages of development for the treatment of these conditions. This review discusses the rationale for the use of some of these anti-inflammatory treatments in patients with diabetes and what we could expect from their use. Future immunomodulatory treatments may not target a specific disease, but could instead act on a dysfunctional pathway that causes several conditions associated with the metabolic syndrome.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use*
  • Clinical Trials as Topic
  • Diabetes Complications / prevention & control
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / immunology
  • Diabetes Mellitus, Type 2 / metabolism
  • Drug Evaluation, Preclinical
  • Drugs, Investigational / adverse effects
  • Drugs, Investigational / pharmacology
  • Drugs, Investigational / therapeutic use*
  • Evidence-Based Medicine*
  • Humans
  • Metabolic Syndrome / complications
  • Metabolic Syndrome / prevention & control
  • Models, Biological*
  • Molecular Targeted Therapy* / adverse effects


  • Anti-Inflammatory Agents
  • Drugs, Investigational